{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:36:25Z","timestamp":1791689785866,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["SCH\/139\/Non-NET \/File no. 1818"],"award-info":[{"award-number":["SCH\/139\/Non-NET \/File no. 1818"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["191620036290"],"award-info":[{"award-number":["191620036290"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institution of Eminence (IoE), University of Delhi","award":["IoE\/2023-24\/12\/FRP"],"award-info":[{"award-number":["IoE\/2023-24\/12\/FRP"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11030-025-11120-x","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T09:14:58Z","timestamp":1738574098000},"page":"5925-5953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Discovery of novel A2AR antagonist via 3D-QSAR pharmacophore modeling: neuroprotective effects in 6-OHDA-induced SH-SY5Y cells and haloperidol-induced Parkinsonism in C57 bl\/6 mice"],"prefix":"10.1007","volume":"29","author":[{"given":"Ankit","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amresh","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratibha Mehta","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"11120_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-540-89615-9_1","volume-title":"Introduction to adenosine receptors as therapeutic targets. Adenosine receptors in health and disease","author":"KA Jacobson","year":"2009","unstructured":"Jacobson KA (2009) Introduction to adenosine receptors as therapeutic targets. Adenosine receptors in health and disease. Springer, Berlin, pp 1\u201324"},{"issue":"2","key":"11120_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1517\/14728214.8.2.537","volume":"8","author":"L Yan","year":"2003","unstructured":"Yan L, Burbiel JC, Maa\u00df A, M\u00fcller CE (2003) Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 8(2):537\u2013576","journal-title":"Expert Opin Emerg Drugs"},{"issue":"3","key":"11120_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrd1983","volume":"5","author":"KA Jacobson","year":"2006","unstructured":"Jacobson KA, Gao Z-G (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discovery 5(3):247\u2013264","journal-title":"Nat Rev Drug Discovery"},{"issue":"1\u20132","key":"11120_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2006.05.003","volume":"248","author":"A Kalda","year":"2006","unstructured":"Kalda A, Yu L, Oztas E, Chen J-F (2006) Novel neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson\u2019s disease. J Neurol Sci 248(1\u20132):9\u201315","journal-title":"J Neurol Sci"},{"key":"11120_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxlet.2021.12.003","volume":"356","author":"X Yuan","year":"2022","unstructured":"Yuan X, Tian Y, Liu C, Zhang Z (2022) Environmental factors in Parkinson\u2019s disease: new insights into the molecular mechanisms. Toxicol Lett 356:1\u201310","journal-title":"Toxicol Lett"},{"issue":"11","key":"11120_CR6","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/cbdv.200490122","volume":"1","author":"LC Chang","year":"2004","unstructured":"Chang LC, Brussee J (2004) Non-xanthine antagonists for the adenosine A1 receptor. Chem biodivers 1(11):1591\u20131626","journal-title":"Chem biodivers"},{"issue":"1","key":"11120_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1021\/cr0682195","volume":"108","author":"PG Baraldi","year":"2008","unstructured":"Baraldi PG, Tabrizi MA, Gessi S, Borea PA (2008) Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem Rev 108(1):238\u2013263","journal-title":"Chem Rev"},{"issue":"17","key":"11120_CR8","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1016\/j.bmcl.2010.06.138","volume":"20","author":"AG Sams","year":"2010","unstructured":"Sams AG, Mikkelsen GK, Larsen M, Torup L, Brennum LT, Schr\u00f8der TJ et al (2010) Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists. Bioorg Med Chem Lett 20(17):5241\u20135244","journal-title":"Bioorg Med Chem Lett"},{"key":"11120_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-39725-7","volume-title":"Purinergic receptors and their modulators","author":"V Colotta","year":"2023","unstructured":"Colotta V, Supuran CT (2023) Purinergic receptors and their modulators. Springer, Cham"},{"key":"11120_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-90808-3_5","author":"S Baraldi","year":"2018","unstructured":"Baraldi S, Baraldi PG, Oliva P, Toti KS, Ciancetta A, Jacobson KA (2018) A 2A adenosine receptor: structures, modeling, and medicinal chemistry. Adeno Recept. https:\/\/doi.org\/10.1007\/978-3-319-90808-3_5","journal-title":"Adeno Recept"},{"key":"11120_CR11","first-page":"101","volume-title":"Adenosine A2A receptor antagonists: chemistry, SARs, and therapeutic potential purinergic receptors and their modulators","author":"A Spinaci","year":"2023","unstructured":"Spinaci A, Buccioni M, Chang C, Dal Ben D, Francucci B, Lambertucci C et al (2023) Adenosine A2A receptor antagonists: chemistry, SARs, and therapeutic potential purinergic receptors and their modulators. Springer, Cham, pp 101\u2013141"},{"issue":"3","key":"11120_CR12","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.bmcl.2009.11.133","volume":"20","author":"PM Luthra","year":"2010","unstructured":"Luthra PM, Mishra CB, Jha PK, Barodia SK (2010) Synthesis of novel 7-imino-2-thioxo-3, 7-dihydro-2H-thiazolo [4, 5-d] pyrimidine derivatives as adenosine A2A receptor antagonists. Bioorg Med Chem Lett 20(3):1214\u20131218","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"11120_CR13","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1021\/jm100240h","volume":"53","author":"J Carlsson","year":"2010","unstructured":"Carlsson J, Yoo L, Gao Z-G, Irwin JJ, Shoichet BK, Jacobson KA (2010) Structure-based discovery of A2A adenosine receptor ligands. J Med Chem 53(9):3748\u20133755","journal-title":"J Med Chem"},{"issue":"7","key":"11120_CR14","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1016\/j.bmc.2010.02.048","volume":"18","author":"CB Mishra","year":"2010","unstructured":"Mishra CB, Barodia SK, Prakash A, Kumar JS, Luthra PM (2010) Novel 8-(furan-2-yl)-3-substituted thiazolo [5, 4-e][1, 2, 4] triazolo [1, 5-c] pyrimidine-2 (3H)-thione derivatives as potential adenosine A2A receptor antagonists. Bioorg Med Chem 18(7):2491\u20132500","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"11120_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2010.08.006","volume":"488","author":"SK Barodia","year":"2011","unstructured":"Barodia SK, Mishra CB, Prakash A, Kumar JS, Kumari N, Luthra PM (2011) Novel 8-(furan-2-yl)-3-benzyl thiazolo [5, 4-e][1, 2, 4] triazolo [1, 5-c] pyrimidine-2 (3H)-thione as selective adenosine A2A receptor antagonist. Neurosci Lett 488(1):1\u20135","journal-title":"Neurosci Lett"},{"issue":"19","key":"11120_CR16","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1016\/j.bmc.2013.07.005","volume":"21","author":"CB Mishra","year":"2013","unstructured":"Mishra CB, Sharma D, Prakash A, Kumari N, Kumar N, Luthra PM (2013) Design and synthesis of (4E)-4-(4-substitutedbenzylideneamino)-3-substituted-2, 3-dihydro-2-thioxothiazole-5-carbonitrile as novel A2A receptor antagonists. Bioorg Med Chem 21(19):6077\u20136083","journal-title":"Bioorg Med Chem"},{"key":"11120_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.neulet.2013.10.035","volume":"558","author":"N Kumari","year":"2014","unstructured":"Kumari N, Mishra CB, Prakash A, Kumar N, Mongre R, Luthra PM (2014) 8-(Furan-2-yl)-3-phenethylthiazolo [5, 4-e][1, 2, 4] triazolo [1, 5-c] pyrimidine-2 (3H)-thione as novel, selective and potent adenosine A2A receptor antagonist. Neurosci Lett 558:203\u2013207","journal-title":"Neurosci Lett"},{"key":"11120_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2024.08.008","author":"J Mishra","year":"2024","unstructured":"Mishra J, Walecha V, Sophronea T, Singh A, Agrawal S, Luthra PM (2024) BBPT attenuated 6-OHDA-induced toxicity by modulating oxidative stress, apoptotic, and inflammatory proteins in primary neurons and rat models of Parkinson\u2019s disease. Neurotoxicology. https:\/\/doi.org\/10.1016\/j.neuro.2024.08.008","journal-title":"Neurotoxicology"},{"issue":"2","key":"11120_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1021\/jm900817u","volume":"53","author":"AR Leach","year":"2010","unstructured":"Leach AR, Gillet VJ, Lewis RA, Taylor R (2010) Three-dimensional pharmacophore methods in drug discovery. J Med Chem 53(2):539\u2013558","journal-title":"J Med Chem"},{"key":"11120_CR20","doi-asserted-by":"publisher","first-page":"129845","DOI":"10.1016\/j.molstruc.2020.129845","volume":"1229","author":"W Sobhi","year":"2021","unstructured":"Sobhi W, Attoui A, Lemaoui T, Erto A, Benguerba Y (2021) In silico drug discovery of acetylcholinesterase and butyrylcholinesterase enzymes inhibitors based on quantitative structure-activity relationship (QSAR) and drug-likeness evaluation. J Mol Struct 1229:129845","journal-title":"J Mol Struct"},{"issue":"1","key":"11120_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1021\/ci600343x","volume":"47","author":"T Hou","year":"2007","unstructured":"Hou T, Wang J, Zhang W, Xu X (2007) ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification. J Chem Inf Model 47(1):208\u2013218","journal-title":"J Chem Inf Model"},{"issue":"1","key":"11120_CR22","doi-asserted-by":"publisher","first-page":"6480804","DOI":"10.1155\/2021\/6480804","volume":"2021","author":"S Mirzaei","year":"2021","unstructured":"Mirzaei S, Ghodsi R, Hadizadeh F, Sahebkar A (2021) 3D-QSAR-based pharmacophore modeling, virtual screening, and molecular docking studies for identification of tubulin inhibitors with potential anticancer activity. Biomed Res Int 2021(1):6480804","journal-title":"Biomed Res Int"},{"key":"11120_CR23","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s00726-012-1218-x","volume":"43","author":"A Prakash","year":"2012","unstructured":"Prakash A, Luthra PM (2012) Insilico study of the A 2A R-D 2 R kinetics and interfacial contact surface for heteromerization. Amino Acids 43:1451\u20131464","journal-title":"Amino Acids"},{"issue":"17","key":"11120_CR24","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1021\/jo00096a008","volume":"59","author":"HP Nestler","year":"1994","unstructured":"Nestler HP, Bartlett PA, Still WC (1994) A general method for molecular tagging of encoded combinatorial chemistry libraries. J Org Chem 59(17):4723\u20134724","journal-title":"J Org Chem"},{"issue":"5","key":"11120_CR25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.bmcl.2009.01.042","volume":"19","author":"Y Shao","year":"2009","unstructured":"Shao Y, Cole AG, Brescia MR, Qin LY, Duo J, Stauffer TM et al (2009) Synthesis and SAR studies of trisubstituted purinones as potent and selective adenosine A2A receptor antagonists. Bioorg Med Chem Lett 19(5):1399\u20131402","journal-title":"Bioorg Med Chem Lett"},{"issue":"5905","key":"11120_CR26","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1126\/science.1164772","volume":"322","author":"V-P Jaakola","year":"2008","unstructured":"Jaakola V-P, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR et al (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322(5905):1211\u20131217","journal-title":"Science"},{"issue":"40","key":"11120_CR27","doi-asserted-by":"publisher","first-page":"29248","DOI":"10.1074\/jbc.M705077200","volume":"282","author":"CS Sum","year":"2007","unstructured":"Sum CS, Tikhonova IG, Neumann S, Engel S, Raaka BM, Costanzi S et al (2007) Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem 282(40):29248\u201329255","journal-title":"J Biol Chem"},{"issue":"9","key":"11120_CR28","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1021\/jm9001346","volume":"52","author":"T Klabunde","year":"2009","unstructured":"Klabunde T, Giegerich C, Evers A (2009) Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. J Med Chem 52(9):2923\u20132932","journal-title":"J Med Chem"},{"key":"11120_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.neuro.2012.10.003","volume":"34","author":"SR Kopalli","year":"2013","unstructured":"Kopalli SR, Noh SJ, Koppula S, Suh YH (2013) Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson\u2019s disease. Neurotoxicology 34:25\u201332","journal-title":"Neurotoxicology"},{"issue":"4","key":"11120_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/antiox10040539","volume":"10","author":"S Cirmi","year":"2021","unstructured":"Cirmi S, Maugeri A, Lombardo GE, Russo C, Musumeci L, Gangemi S et al (2021) A flavonoid-rich extract of mandarin juice counteracts 6-OHDA-induced oxidative stress in SH-SY5Y cells and modulates Parkinson-related genes. Antioxidants 10(4):539","journal-title":"Antioxidants"},{"issue":"5","key":"11120_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10822-010-9352-6","volume":"24","author":"D Seeliger","year":"2010","unstructured":"Seeliger D, de Groot BL (2010) Ligand docking and binding site analysis with PyMOL and Autodock\/Vina. J Comput Aided Mol Des 24(5):417\u2013422","journal-title":"J Comput Aided Mol Des"},{"issue":"3","key":"11120_CR32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.pharmthera.2011.07.004","volume":"132","author":"MT Armentero","year":"2011","unstructured":"Armentero MT, Pinna A, Ferr\u00e9 S, Lanciego JL, M\u00fcller CE, Franco R (2011) Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson\u2019s disease. Pharmacol Ther 132(3):280\u2013299","journal-title":"Pharmacol Ther"},{"issue":"2","key":"11120_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jcc.540160205","volume":"16","author":"A Smellie","year":"1995","unstructured":"Smellie A, Teig SL, Towbin P (1995) Poling: promoting conformational variation. J Comput Chem 16(2):171\u2013187","journal-title":"J Comput Chem"},{"key":"11120_CR34","doi-asserted-by":"publisher","first-page":"105526","DOI":"10.1016\/j.compbiomed.2022.105526","volume":"146","author":"A Raafat","year":"2022","unstructured":"Raafat A, Mowafy S, Abouseri SM, Fouad MA, Farag NA (2022) Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation. Comput Biol Med 146:105526","journal-title":"Comput Biol Med"},{"key":"11120_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1023\/A:1025386326946","volume":"17","author":"A Golbraikh","year":"2003","unstructured":"Golbraikh A, Shen M, Xiao Z, Xiao Y-D, Lee K-H (2003) Tropsha AJJoc-amd. Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des 17:241\u2013253","journal-title":"J Comput Aided Mol Des"},{"issue":"3","key":"11120_CR36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.18596\/jotcsa.927426","volume":"8","author":"MT Muhammed","year":"2021","unstructured":"Muhammed MT, Ak\u0131-yalc\u0131n E (2021) Pharmacophore modeling in drug discovery: methodology and current status. J Turk Chem Soc Sect A Chem 8(3):749\u2013762","journal-title":"J Turk Chem Soc Sect A Chem"},{"issue":"5","key":"11120_CR37","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s11030-022-10540-3","volume":"27","author":"P Poonia","year":"2023","unstructured":"Poonia P, Sharma M, Jha P, Chopra M (2023) Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors. Mol Divers 27(5):2053\u20132071","journal-title":"Mol Divers"},{"issue":"38","key":"11120_CR38","first-page":"39873","volume":"9","author":"V Teotia","year":"2024","unstructured":"Teotia V, Jha P, Chopra M (2024) Discovery of potential inhibitors of CDK1 by integrating pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation studies, and evaluation of their inhibitory activity. ACS Omega 9(38):39873\u201339892","journal-title":"ACS Omega"},{"key":"11120_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2024.2443130","author":"D Kaur","year":"2024","unstructured":"Kaur D, Saluja D, Chopra M (2024) Identification of novel inhibitors of cancer target telomerase using a dual structure-based pharmacophore approach to virtually screen libraries, molecular docking and validation by molecular dynamics simulations. J Biomol Struct Dynam. https:\/\/doi.org\/10.1080\/07391102.2024.2443130","journal-title":"J Biomol Struct Dynam"},{"issue":"11","key":"11120_CR40","first-page":"5096","volume":"41","author":"P Jha","year":"2023","unstructured":"Jha P, Saluja D, Chopra M (2023) Structure-guided pharmacophore based virtual screening, docking, and molecular dynamics to discover repurposed drugs as novel inhibitors against endoribonuclease Nsp15 of SARS-CoV-2. J Biomol Struct Dyn 41(11):5096\u20135106","journal-title":"J Biomol Struct Dyn"},{"issue":"30","key":"11120_CR41","doi-asserted-by":"publisher","first-page":"9388","DOI":"10.1002\/slct.202001419","volume":"5","author":"P Debnath","year":"2020","unstructured":"Debnath P, Debnath B, Bhaumik S, Debnath S (2020) In silico identification of potential inhibitors of ADP-ribose phosphatase of SARS-CoV-2 nsP3 by combining E-pharmacophore-and receptor-based virtual screening of database. ChemistrySelect 5(30):9388\u20139398","journal-title":"ChemistrySelect"},{"key":"11120_CR42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S1574-1400(06)02007-X","volume":"2","author":"A Tropsha","year":"2006","unstructured":"Tropsha A (2006) Variable selection qsar modeling, model validation, and virtual screening. Ann Rep Comput Chem 2:113\u2013126","journal-title":"Ann Rep Comput Chem"},{"key":"11120_CR43","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejmech.2016.01.034","volume":"110","author":"DA AlQudah","year":"2016","unstructured":"AlQudah DA, Zihlif MA, Taha MO (2016) Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors. Eur J Med Chem 110:204\u2013223","journal-title":"Eur J Med Chem"},{"issue":"2","key":"11120_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/encyclopedia3020035","volume":"3","author":"S Kralj","year":"2023","unstructured":"Kralj S, Juki\u010d M, Bren U (2023) Molecular filters in medicinal chemistry. Encyclopedia 3(2):501\u2013511","journal-title":"Encyclopedia"},{"key":"11120_CR45","doi-asserted-by":"publisher","first-page":"102988","DOI":"10.1016\/j.bioorg.2019.102988","volume":"89","author":"MK Sobhy","year":"2019","unstructured":"Sobhy MK, Mowafy S, Lasheen DS, Farag NA, Abouzid KA (2019) 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: design, synthesis and biological evaluation. Bioorg Chem 89:102988","journal-title":"Bioorg Chem"},{"key":"11120_CR46","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"H Pajouhesh","year":"2005","unstructured":"Pajouhesh H, Lenz GR (2005) Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2:541\u2013553","journal-title":"NeuroRx"},{"key":"11120_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-015-0033-1","volume":"4","author":"L Wei","year":"2015","unstructured":"Wei L, Ding L, Mo MS, Lei M, Zhang L, Chen K et al (2015) Wnt3a protects SH-SY5Y cells against 6-hydroxydopamine toxicity by restoration of mitochondria function. Transl Neurodegener 4:1\u20138","journal-title":"Transl Neurodegener"},{"key":"11120_CR48","doi-asserted-by":"publisher","first-page":"631501","DOI":"10.3389\/fnins.2021.631501","volume":"15","author":"Z Xu","year":"2021","unstructured":"Xu Z, Yang D, Huang X, Huang H (2021) Astragaloside IV protects 6-hydroxydopamine-induced SH-SY5Y cell model of Parkinson\u2019s disease via activating the JAK2\/STAT3 pathway. Front Neurosci 15:631501","journal-title":"Front Neurosci"},{"key":"11120_CR49","doi-asserted-by":"publisher","first-page":"105793","DOI":"10.1016\/j.neuint.2024.105793","volume":"178","author":"T Sophronea","year":"2024","unstructured":"Sophronea T, Agrawal S, Kumari N, Mishra J, Walecha V, Luthra PM (2024) A2AR antagonists triggered the AMPK\/m-TOR autophagic pathway to reverse the calcium-dependent cell damage in 6-OHDA induced model of PD. Neurochem Int 178:105793","journal-title":"Neurochem Int"},{"key":"11120_CR50","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neulet.2018.03.040","volume":"675","author":"N Kumari","year":"2018","unstructured":"Kumari N, Agrawal S, Kumari R, Sharma D, Luthra PM (2018) Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2, 3-dihydrothiazolo [4, 5-d] pyrimidin-6 (7H)-yl) urea) in 6-OHDA induced rodent model of hemiparkinson\u2019s disease. Neurosci Lett 675:74\u201382","journal-title":"Neurosci Lett"},{"issue":"3","key":"11120_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s12192-019-00993-1","volume":"24","author":"M-X Zhao","year":"2019","unstructured":"Zhao M-X, Wen J-L, Wang L, Wang X-P, Chen T-S (2019) Intracellular catalase activity instead of glutathione level dominates the resistance of cells to reactive oxygen species. Cell Stress Chaperones 24(3):609\u2013619","journal-title":"Cell Stress Chaperones"},{"issue":"3","key":"11120_CR52","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1432-1033.1974.tb03714.x","volume":"47","author":"S Marklund","year":"1974","unstructured":"Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47(3):469\u2013474","journal-title":"Eur J Biochem"},{"issue":"05","key":"11120_CR53","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.15419\/bmrat.v4i05.169","volume":"4","author":"A Saeed","year":"2017","unstructured":"Saeed A, Shakir L, Khan MA, Ali A, Zaidi AA (2017) Haloperidol induced Parkinson\u2019s disease mice model and motor-function modulation with Pyridine-3-carboxylic acid. Biomed Res Ther 4(05):1305\u20131317","journal-title":"Biomed Res Ther"},{"issue":"7","key":"11120_CR54","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.3390\/molecules27072366","volume":"27","author":"A Mori","year":"2022","unstructured":"Mori A, Chen J-F, Uchida S, Durlach C, King SM, Jenner P (2022) The pharmacological potential of adenosine A2A receptor antagonists for treating Parkinson\u2019s disease. Molecules 27(7):2366","journal-title":"Molecules"},{"issue":"2","key":"11120_CR55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.59566\/IJBS.2008.4089","volume":"4","author":"LA Pham-Huy","year":"2008","unstructured":"Pham-Huy LA, He H, Pham-Huy C (2008) Free radicals, antioxidants in disease and health. Int J Biomed Sci IJBS 4(2):89","journal-title":"Int J Biomed Sci IJBS"},{"key":"11120_CR56","doi-asserted-by":"publisher","first-page":"135222","DOI":"10.1016\/j.neulet.2020.135222","volume":"735","author":"A Masih","year":"2020","unstructured":"Masih A, Singh S, Agnihotri AK, Giri S, Shrivastava JK, Pandey N et al (2020) Design and development of 1, 3, 5-triazine-thiadiazole hybrids as potent adenosine A2A receptor (A2AR) antagonist for benefit in Parkinson\u2019s disease. Neurosci Lett 735:135222","journal-title":"Neurosci Lett"},{"issue":"2","key":"11120_CR57","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1021\/acs.jmedchem.6b01584","volume":"60","author":"S Basu","year":"2017","unstructured":"Basu S, Barawkar DA, Thorat S, Shejul YD, Patel M, Naykodi M et al (2017) Design, synthesis of novel, potent, selective, orally bioavailable adenosine A2A receptor antagonists and their biological evaluation. J Med Chem 60(2):681\u2013694","journal-title":"J Med Chem"},{"key":"11120_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13321-021-00492-5","volume":"13","author":"L Kalash","year":"2021","unstructured":"Kalash L, Winfield I, Safitri D, Bermudez M, Carvalho S, Glen R et al (2021) Structure-based identification of dual ligands at the A 2A R and PDE10A with anti-proliferative effects in lung cancer cell-lines. J Cheminf 13:1\u201317","journal-title":"J Cheminf"},{"issue":"7","key":"11120_CR59","doi-asserted-by":"publisher","first-page":"774","DOI":"10.2174\/1381612825666190306162006","volume":"25","author":"N Agrawal","year":"2019","unstructured":"Agrawal N, Chandrasekaran B, Al-Aboudi A (2019) Recent advances in the in-silico structure-based and ligand-based approaches for the design and discovery of agonists and antagonists of A2A adenosine receptor. Curr Pharm Des 25(7):774\u2013782","journal-title":"Curr Pharm Des"},{"issue":"1","key":"11120_CR60","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1021\/jm010360c","volume":"45","author":"AK Debnath","year":"2002","unstructured":"Debnath AK (2002) Pharmacophore mapping of a series of 2, 4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase. J Med Chem 45(1):41\u201353","journal-title":"J Med Chem"},{"key":"11120_CR61","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.parkreldis.2020.10.024","volume":"80","author":"J-F Chen","year":"2020","unstructured":"Chen J-F, Schwarzschild MA (2020) Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson\u2019s disease? Parkinsonism Relat Disord 80:S45\u2013S53","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"11120_CR62","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/sj.bjp.0705388","volume":"139","author":"N Yoshimura","year":"2003","unstructured":"Yoshimura N, Kuno S, Chancellor MB, De Groat WC, Seki S (2003) Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway. Br J Pharmacol 139(8):1425\u20131432","journal-title":"Br J Pharmacol"},{"key":"11120_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-1-62703-640-5_2","volume-title":"Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Neuronal cell culture: methods and protocols","author":"J Kovalevich","year":"2013","unstructured":"Kovalevich J, Langford D (2013) Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Neuronal cell culture: methods and protocols. Humana Press, Totowa, pp 9\u201321"},{"issue":"1","key":"11120_CR64","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1471-4159.2011.07178.x","volume":"117","author":"N Rebola","year":"2011","unstructured":"Rebola N, Sim\u00f5es AP, Canas PM, Tom\u00e9 AR, Andrade GM, Barry CE et al (2011) Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J Neurochem 117(1):100\u2013111","journal-title":"J Neurochem"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11120-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11120-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11120-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:02:39Z","timestamp":1764784959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11120-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["11120"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11120-x","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The author would like to thank the Department\u2019s Animal Ethics Committee for approval of the animal project (Proposal no. IAEC\/ACBR\/August 2023\/PML\/03).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}